Predicting Hypertension Subtypes with Machine Learning Using Targeted Metabolites and Their Ratios.
Cushing syndrome
biomarkers
hypertension
machine learning
metabolomics
pheochromocytoma/paraganglioma
primary aldosteronism
Journal
Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790
Informations de publication
Date de publication:
16 Aug 2022
16 Aug 2022
Historique:
received:
16
06
2022
revised:
02
08
2022
accepted:
04
08
2022
entrez:
25
8
2022
pubmed:
26
8
2022
medline:
26
8
2022
Statut:
epublish
Résumé
Hypertension is a major global health problem with high prevalence and complex associated health risks. Primary hypertension (PHT) is most common and the reasons behind primary hypertension are largely unknown. Endocrine hypertension (EHT) is another complex form of hypertension with an estimated prevalence varying from 3 to 20% depending on the population studied. It occurs due to underlying conditions associated with hormonal excess mainly related to adrenal tumours and sub-categorised: primary aldosteronism (PA), Cushing's syndrome (CS), pheochromocytoma or functional paraganglioma (PPGL). Endocrine hypertension is often misdiagnosed as primary hypertension, causing delays in treatment for the underlying condition, reduced quality of life, and costly antihypertensive treatment that is often ineffective. This study systematically used targeted metabolomics and high-throughput machine learning methods to predict the key biomarkers in classifying and distinguishing the various subtypes of endocrine and primary hypertension. The trained models successfully classified CS from PHT and EHT from PHT with 92% specificity on the test set. The most prominent targeted metabolites and metabolite ratios for hypertension identification for different disease comparisons were C18:1, C18:2, and Orn/Arg. Sex was identified as an important feature in CS vs. PHT classification.
Identifiants
pubmed: 36005627
pii: metabo12080755
doi: 10.3390/metabo12080755
pmc: PMC9416693
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : European Union's Horizon 2020
ID : 633983
Organisme : Clinical Research Priority Program of the University of Zurich for the CRPP HYRENE
Références
Bioinformatics. 2001 Jun;17(6):520-5
pubmed: 11395428
J Hypertens. 2020 Aug;38(8):1443-1456
pubmed: 32412940
Diabetes Metab. 2020 Feb;46(1):1-7
pubmed: 30825519
Transl Psychiatry. 2020 May 19;10(1):157
pubmed: 32427830
J Neuroendocrinol. 2022 Mar 4;:e13113
pubmed: 35312199
Pol Arch Intern Med. 2017 Sep 29;127(9):628-630
pubmed: 28984283
Arch Dermatol Res. 2017 Sep;309(7):519-528
pubmed: 28695330
PLoS One. 2019 Apr 18;14(4):e0214121
pubmed: 30998683
Nat Rev Nephrol. 2020 Apr;16(4):223-237
pubmed: 32024986
J Hypertens. 2020 Oct;38(10):1919-1928
pubmed: 32890264
Exp Clin Endocrinol Diabetes. 2019 Feb;127(2-03):129-136
pubmed: 30011405
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
Genet Epidemiol. 2007 May;31(4):306-15
pubmed: 17323372
Curr Protoc Mol Biol. 2012 Apr;Chapter 30:Unit 30.2.1-24
pubmed: 22470063
Curr Protoc Bioinformatics. 2019 Dec;68(1):e86
pubmed: 31756036
Alzheimers Dement. 2016 Jul;12(7):815-22
pubmed: 26806385
Bioinformatics. 2004 Nov 22;20(17):2985-96
pubmed: 15180934
Eur J Endocrinol. 2019 Dec;181(6):647-657
pubmed: 31614337
Front Genet. 2019 May 16;10:452
pubmed: 31156708
J Clin Endocrinol Metab. 2021 Mar 25;106(4):1111-1128
pubmed: 33382876
Eur J Endocrinol. 2017 Aug;177(2):227-237
pubmed: 28566446
Neuroimage. 2011 May 15;56(2):809-13
pubmed: 20483379
Neuroimage Clin. 2016 Jul 27;12:320-31
pubmed: 27551669
Gigascience. 2018 Jul 1;7(7):
pubmed: 29790950
JCI Insight. 2019 Sep 5;4(17):
pubmed: 31484828
Lab Chip. 2018 Jan 30;18(3):395-405
pubmed: 29192299